Wells Fargo & Company Arcus Biosciences, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RCUS
# of Institutions
207Shares Held
49MCall Options Held
173KPut Options Held
151K-
Black Rock Inc. New York, NY9.76MShares$161 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$86.7 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA4.25MShares$70 Million0.65% of portfolio
-
State Street Corp Boston, MA3.06MShares$50.4 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.83MShares$30.2 Million0.08% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.19B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...